You are here

Study Suggests Alvimopan Improves Time to Recovery in Postoperative Ileus

EXTON, Pa., April 2 /PRNewswire-FirstCall/ -- Adolor Corporation (NASDAQ:ADLR) announced today top-line results of its first Phase 3 clinical study (14CL302) for its novel product candidate, alvimopan, in the management of postoperative ileus ("POI").

A statistically significant difference was achieved in the primary endpoint of the study, time to recovery of gastrointestinal function, in patients in the alvimopan 6 mg treatment group compared to patients in the placebo group (Cox proportional hazard model; hazard ratio = 1.47; P Alvimopan was generally well tolerated in this study. The most frequently observed adverse events in both the placebo and treatment groups were nausea, vomiting and hypotension.

"We are delighted to have completed a major milestone in our alvimopan Phase 3 clinical program in postoperative ileus. We believe the results of this study support our goal of submitting a New Drug Application for alvimopan in 2003. We look forward to completing the accrual of our additional alvimopan postoperative ileus clinical studies, which will need to confirm the results of the 302 study in order to file a New Drug Application," commented Bruce A. Peacock, President and Chief Executive Officer of Adolor.

Study 14CL302 was a double-blind, placebo-controlled, multi-centered study that enrolled approximately 450 patients who were scheduled to undergo partial colectomies, simple or radical hysterectomies and to receive opioid analgesics. Patients were randomized in three arms of 150 each to receive placebo, 6 mg or 12 mg doses of alvimopan, at least two hours prior to surgery, and then twice a day beginning on the first postoperative day until hospital discharge or for a maximum of seven days postoperative treatment. The primary endpoint of the study was a composite measure of the time to recovery of both lower and upper gastrointestinal function as defined by time to first flatus or first bowel movement and time to tolerability of solid foods, whichever last occurred.

About Postoperative Ileus
Many patients undergoing major abdominal surgery experience temporary bowel impairment of variable duration. This phenomenon, known as postoperative ileus or POI, may be exacerbated and prolonged by both the degree of bowel manipulation and the use of opioid analgesics for pain relief. POI is characterized by abdominal distention or bloating, nausea and vomiting, accumulation of gas and fluids in the bowel, and delays in passage of flatus or delays in defecation. There has been little advance in the treatment of POI since the introduction of nasogastric decompression which has limited effectiveness and is uncomfortable for patients. There are no FDA-approved therapies for the management of POI currently available. There is a need for improved treatments because postoperative ileus can have a negative impact on patient recovery and health care costs.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs